Get Live Data

Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share News
  5. UK BROKER RATINGS SUMMARY: Peel Hunt Initiates Whitbread With Buy

Pin to quick picksGlaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,653.00
Bid: 1,654.00
Ask: 1,654.50
Change: 12.50 (0.76%)
Spread: 0.50 (0.03%)
Open: 1,638.50
High: 1,655.50
Low: 1,634.00
Prev. Close: 1,640.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Peel Hunt Initiates Whitbread With Buy

Mon, 04th Nov 2019 09:10

(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and Friday afternoon:

----------

FTSE 100

----------

PEEL HUNT INITIATES WHITBREAD WITH 'BUY' - TARGET 4800 PENCE

----------

UBS CUTS SAGE GROUP PRICE TARGET TO 620 (625) PENCE - 'SELL'

----------

UBS RAISES STANDARD CHARTERED PRICE TARGET TO 690 (650) PENCE - 'NEUTRAL'

----------

UBS CUTS LLOYDS PRICE TARGET TO 62 (65) PENCE - 'BUY'

----------

JPMORGAN CUTS LLOYDS PRICE TARGET TO 68 (72) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS SMITH & NEPHEW PRICE TARGET TO 1711 (1814) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS EVRAZ PRICE TARGET TO 375 (400) PENCE - 'UNDERWEIGHT'

----------

LIBERUM RAISES GLAXOSMITHKLINE PRICE TARGET TO 1890 (1510) PENCE - 'HOLD'

----------

DEUTSCHE BANK CUTS VODAFONE PRICE TARGET TO 240 (250) PENCE - 'BUY'

----------

DEUTSCHE BANK CUTS RSA INSURANCE PRICE TARGET TO 560 (565) PENCE - 'HOLD'

----------

DEUTSCHE BANK RAISES INTERNATIONAL CONSOLIDATED AIRLINES PRICE TARGET TO 670 (630) PENCE - 'BUY'

----------

GOLDMAN CUTS EXPERIAN PRICE TARGET TO 2500 (2600) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS IMPERIAL BRANDS PRICE TARGET TO 2400 (3800) PENCE - 'BUY'

----------

JEFFERIES CUTS BRITISH AMERICAN TOBACCO PRICE TARGET TO 4800 (4900) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS RECKITT-BENCKISER-PRICE TARGET TO 5550 (5800) PENCE - UNDERPERFORM

----------

CREDIT SUISSE CUTS SMITH & NEPHEW PRICE TARGET TO 1725 (1770) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

LIBERUM RAISES PETS AT HOME TO 'BUY' ('HOLD')

----------

UBS CUTS ELEMENTIS PRICE TARGET TO 175 (185) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES CAPITA GROUP PRICE TARGET TO 140 (120) PENCE - 'HOLD'

----------

BARCLAYS RAISES WORKSPACE GROUP PRICE TARGET TO 1000 (980) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES DERWENT LONDON PRICE TARGET TO 3100 (3000) PENCE - 'UNDERWEIGHT'

----------

BARCLAYS CUTS BBA AVIATION PRICE TARGET TO 347 (350) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES FUTURE PRICE TARGET TO 1755 (1530) PENCE - 'BUY'

----------

BERENBERG CUTS MAN GROUP PRICE TARGET TO 192 (206) PENCE - 'BUY'

----------

BERENBERG CUTS BOVIS HOMES PRICE TARGET TO 1220 (1230) PENCE - 'BUY'

----------

JPMORGAN RAISES TRAVIS PERKINS PRICE TARGET TO 1400 (1356) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS WEIR GROUP PRICE TARGET TO 1395 (1440) PENCE - 'HOLD'

----------

OTHER MAIN MARKET AND AIM

----------

LIBERUM CUTS LOOKERS TO 'HOLD' ('BUY') - TARGET 30 (68) PENCE

----------

BERENBERG RAISES CHEMRING GROUP PRICE TARGET TO 200 (190) PENCE - 'HOLD

----------

BERENBERG RAISES TEAM17 PRICE TARGET TO 375 (330) PENCE - 'BUY'

----------

JPMORGAN CUTS FEVERTREE DRINKS PRICE TARGET TO 2400 (2740) PENCE - 'OVERWEIGHT'

----------

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
456789101112

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.